PuSH - Publikationsserver des Helmholtz Zentrums München

Grandl, G. ; Novikoff, A. ; DiMarchi, R.* ; Tschöp, M.H. ; Müller, T.D.

Gut peptide agonism in the treatment of obesity and diabetes.

Compr. Physiol. 10, 99-124 (2019)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Obesity is a global healthcare challenge that gives rise to devastating diseases such as the metabolic syndrome, type-2 diabetes (T2D), and a variety of cardiovascular diseases. The escalating prevalence of obesity has led to an increased interest in pharmacological options to counteract excess weight gain. Gastrointestinal hormones such as glucagon, amylin, and glucagon-like peptide-1 (GLP-1) are well recognized for influencing food intake and satiety, but the therapeutic potential of these native peptides is overall limited by a short half-life and an often dose-dependent appearance of unwanted effects. Recent clinical success of chemically optimized GLP-1 mimetics with improved pharmacokinetics and sustained action has propelled pharmacological interest in using bioengineered gut hormones to treat obesity and diabetes. In this article, we summarize the basic biology and signaling mechanisms of selected gut peptides and discuss how they regulate systemic energy and glucose metabolism. Subsequently, we focus on the design and evaluation of unimolecular drugs that combine the beneficial effects of selected gut hormones into a single entity to optimize the beneficial impact on systems metabolism.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Dependent Insulinotropic Polypeptide; Diet-induced Obese; Glp-1 Receptor Agonist; Pancreatic Beta-cells; Improves Glycemic Control; Brown Adipose-tissue; Hepatic Glucose-production; Placebo-controlled Trial
ISSN (print) / ISBN 2040-4603
e-ISSN 2040-4603
Zeitschrift Comprehensive Physiology
Quellenangaben Band: 10, Heft: 1, Seiten: 99-124 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Oxford
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)